Tag Archives: iPSC

BlueRock Therapeutics and bit.bio Collaborate on iPSC-Derived T Cell Therapies for Autoimmune Disorders

(IN BRIEF) BlueRock Therapeutics and bit.bio have announced a collaboration and option agreement to discover and manufacture iPSC-derived regulatory T cells (Tregs) for therapeutic use. Tregs are crucial for immune system balance and controlling excessive immune reactions, making them potential … Read the full press release

Bayer to use Mammoth’s CRISPR systems for the development of vivo gene-editing therapies

Agreement strengthens Bayer’s new cell and gene therapy platform further / Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems / Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more … Read the full press release